Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
08 Abril 2024 - 5:30PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that Sean P. Bohen, M.D.,
Ph.D., President and Chief Executive Officer, will participate in a
panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the
2024 CG Horizons in Oncology Virtual Conference on Monday, April
15, 2024, at 2:00 p.m. ET.
About Olema OncologyOlema Oncology
is a clinical-stage biopharmaceutical company committed to
transforming the standard of care and improving outcomes for women
living with cancer. Olema is advancing a pipeline of novel
therapies by leveraging our deep understanding of endocrine-driven
cancers, nuclear receptors, and mechanisms of acquired resistance.
In addition to our lead product candidate, palazestrant (OP-1250),
a proprietary, orally-available complete estrogen receptor (ER)
antagonist (CERAN) and a selective ER degrader (SERD), Olema is
developing a potent KAT6 inhibitor (OP-3136). Olema is
headquartered in San Francisco and has operations in Cambridge,
Massachusetts. For more information, please visit us at
www.olema.com.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024